Impact of Respiratory Syncytial Virus–Confirmed Hospitalizations on Caregivers of US Preterm Infants
Open Access
- 21 April 2019
- journal article
- research article
- Published by SAGE Publications in Clinical Pediatrics
- Vol. 58 (8) , 837-850
Abstract
This study assessed the impact of respiratory syncytial virus–confirmed hospitalizations (RSVH) on caregivers of high-risk preterm infants. Caregivers for infants born at 29 to 35 weeks’ gestational age and hospitalized for confirmed RSV disease responded to measures of self-rated and perceived infant stress (1-7; 7 = very stressful), perceived infant health (0-100; 100 = best imaginable health), and productivity impairment. Data were collected at hospital discharge through 1 month post-discharge. Caregiver responses indicated high stress levels, poor health, and productivity loss were reported at discharge; however, steady improvements were seen through 1 month post-discharge: caregiver-rated stress (from 6 to 2), infant stress (5 to 1), caregiver-perceived infant health (64 to 84), and productivity loss (mothers: 91% to 31%; fathers: 81% to 18%). Qualitative results indicated emotional impact, family routine disruption, financial concerns, and medical concerns persisted at 1 month post-discharge. This study found the caregiver burden of RSVH persists at least 1 month beyond discharge.Keywords
Funding Information
- AstraZeneca
This publication has 23 references indexed in Scilit:
- Parenting Stress Among Caregivers of Children With Chronic Illness: A Systematic ReviewJournal of Pediatric Psychology, 2013
- Measuring economic consequences of preterm birth - Methodological recommendations for the evaluation of personal burden on children and their caregiversHealth Economics Review, 2011
- Modified Recommendations for Use of Palivizumab for Prevention of Respiratory Syncytial Virus InfectionsPediatrics, 2009
- The Impact of Severe Respiratory Syncytial Virus on the Child, Caregiver, and Family During Hospitalization and RecoveryPediatrics, 2005
- Parental concern and distress about infant painArchives of Disease in Childhood - Fetal and Neonatal Edition, 2004
- Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart diseaseThe Journal of Pediatrics, 2003
- Time and Out-of-Pocket Costs Associated with Respiratory Syncytial Virus Hospitalization of InfantsValue in Health, 2003
- Family Reactions During Infants' Hospitalization in the Neonatal Intensive Care UnitAmerican Journal of Perinatology, 2002
- Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk InfantsPediatrics, 1998
- The Validity and Reproducibility of a Work Productivity and Activity Impairment InstrumentPharmacoEconomics, 1993